ECElisabet Casellas‐Pujol

Elisabet Casellas‐Pujol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elisabet Casellas‐Pujol has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    “Skills for pills”: The dialectical‐behavioural therapy skills training reduces polypharmacy in borderline personality disorder

    by Joaquim Soler, Elisabet Casellas‐Pujol, Isabel Fernández‐Felipe, Ana Martín‐Blanco, David Almenta, Juan C. Pascual

    Objective: Polypharmacy and overprescription of off‐label medications are common in patients with borderline personality disorder (BPD). The aim of the present naturalistic study was to explore whether the skills training module of dialectical‐behavioural therapy (DBT) can reduce polypharmacy in these patients in routine clinical practice.Methods: Retrospective, observational study of 377 patients with a primary diagnosis of BPD consecutively admitted to the BPD outpatient unit from 2010 through 2020. All patients were invited to participate in the DBT skills training module (DBT‐ST). DBT‐ST participants (n = 182) were compared with a control group who did not participate in DBT‐ST (n = 195). Pre‐post intervention changes in medication load and use of antidepressants, benzodiazepines, mood stabilizers, and antipsychotics were evaluated.Results: At baseline, most patients (84.4%) were taking at least one medication and 46.9% were on polypharmacy. Compared to controls, patients in the DBT‐ST group presented a significant reduction in the number of medications (2.67–1.95 vs. 2.16–2.19; p < 0.001), medication load (4.25–3.05 vs. 3.45–3.48; p < 0.001), use of benzodiazepines (54.4%–27.5% vs. 40%–40.5%; p < 0.001), mood stabilizers (43.4%–33% vs. 36.4%–39.5%; p < 0.001), and antipsychotics (36.3%–29.1% vs. 34.4%–36.9%; p < 0.001).Conclusions: These findings suggest that patients with BPD can benefit from the DBT‐ST module, which may reduce the medication load, particularly of sedatives. The results suggest that DBT‐ST may be useful to treat overmedication in patients with BPD and could help to promote “deprescription” in clinical practice.